Abstract 24P
Background
Epigenome-wide association studies showed association of the peripheral blood methylation profile with potential immunological aspects such as systemic inflammation in various diseases. Since inflammation is recognized as hallmark in cancer development and progression, DNA methylation profiles of peripheral blood cells may serve as a personalized biomarker in oncology. Here, we aim to explore if the blood DNA methylation signature changes over time in patients with NSCLC treated with immune checkpoint inhibitors.
Methods
Patients diagnosed with treatment-naive metastatic NSCLC at our institution between March 2019 and December 2023 were included. Leukocyte DNA was collected and isolated prior to treatment initiation (BL) and at first restaging (1FU). Methylation analysis was performed with Infinium Methylation EPICv2.0 microarrays. Treatment response was analyzed by a board-certified radiologist according to iRECIST 1.1 and RANO 1.0 criteria.
Results
Forty-one patients (63% males, 37% females; median age 64 years, range 45-83) were analyzed: 32/41 (78%) adenocarcinoma, 6/41 (15%) squamous cell carcinoma, 2/41 (5%) adenosquamous and 1/41 (2%) pleomorphic carcinoma. Chemoimmunotherapy was administered in 31/41 (75.6%) and ICI monotherapy in 10/42 (24.4%) patients. Except one patient who received atezolizumab (PDL-1) all other received pembrolizumab (98%, PD-1). Median days between BL and 1FU was 63 (range 38-214) or 3 cycles of ICI (range 1-6). Of the included patients, 15/41 (36.6%) were classified as responder (iCR or iPR) and 26/41 (63.4%) as non-responder (iSD or iCPD) at first restaging. Durable clinical benefit (disease control > 6 months) was achieved in 28/41 (68.3%) patients. Based on the 500 most differentially methylated CpG sites in their blood DNA methylation profiles we could not demonstrate differences between BL and 1FU.
Conclusions
In our analysis, the blood methylation profile of patients with NSCLC was stable between baseline and follow up, implying that the blood DNA methylation profile is a stabile biomarker not influenced by therapy. Further analysis of the correlation with treatment response are currently ongoing.
Legal entity responsible for the study
The authors.
Funding
The financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association is gratefully acknowledged.
Disclosure
M. Preusser: Financial Interests, Personal and Institutional, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Lehrman Group (GLG), CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Boehringer Ingelheim, Telix Medscape, OncLive; Financial Interests, Personal and Institutional, Advisory Role: Gerson. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, CeCaVa, Seagen, Alexion, Servier; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche; Non-Financial Interests, Personal, Leadership Role, Board Member: European Association of Neuro-Oncology. All other authors have declared no conflicts of interest.
Resources from the same session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract
134P - Intracranial (IC) progression-free survival (PFS) with ivonescimab (Ivo) compared to placebo in the HARMONi-A trial of patients (Pts) with previously treated EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract